BiomX (NYSEMKT:PHGE) Trading Up 1.6%

BiomX Inc. (NYSEMKT:PHGE)’s stock price was up 1.6% on Tuesday . The company traded as high as $0.34 and last traded at $0.34. Approximately 46,711 shares traded hands during trading, a decline of 32% from the average daily volume of 68,601 shares. The stock had previously closed at $0.33.

Wall Street Analyst Weigh In

A number of brokerages recently commented on PHGE. Laidlaw began coverage on shares of BiomX in a research note on Tuesday, May 28th. They issued a “buy” rating and a $2.50 price objective on the stock. HC Wainwright reissued a “buy” rating and issued a $2.00 price objective on shares of BiomX in a research note on Tuesday, May 21st.

BiomX Trading Down 8.3 %

The company has a market capitalization of $23.25 million, a PE ratio of -0.55 and a beta of 1.32. The company has a debt-to-equity ratio of 0.51, a quick ratio of 2.84 and a current ratio of 2.84. The business has a fifty day moving average price of $0.35 and a 200 day moving average price of $0.32.

Institutional Trading of BiomX

A hedge fund recently bought a new stake in BiomX stock. Ikarian Capital LLC acquired a new stake in BiomX Inc. (NYSEMKT:PHGE) in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 10,817,327 shares of the company’s stock, valued at approximately $4,868,000. Ikarian Capital LLC owned approximately 19.59% of BiomX as of its most recent SEC filing. 40.57% of the stock is owned by hedge funds and other institutional investors.

About BiomX

BiomX Inc, a clinical-stage biopharmaceutical company, develops products using natural and engineered phage technologies designed to target and kill specific harmful bacteria associated with chronic disease. It is developing BX211, a phage therapy, which is in phase 2 clinical study for the treatment of diabetic foot osteomyelitis.